Recombinant adeno-associated viruses (rAAVs) stand at the forefront of gene therapy
applications, holding immense significance for their safe and efficient gene delivery …

Efficient manufacture of recombinant adeno-associated virus (rAAV) vectors for gene
therapy remains challenging. Packaging cell lines containing stable integration of the AAV …

The design of biomanufacturing platforms based on viral transduction and/or propagation
poses significant challenges at the intersection between synthetic biology and process …

Gene therapy is poised to transition from niche to mainstream medicine, with recombinant
adeno-associated virus (rAAV) as the vector of choice. However, this requires robust …

AAV is a widely used vector for in vivo gene delivery that often requires considerable
manufacturing capacity. However, current manufacturing techniques are inefficient, leading …

Biotherapeutics, particularly monoclonal antibodies (mAbs) and recombinant adeno-
associated viruses (rAAVs), have transformed the treatment landscape for various diseases …

The pressing demands for efficient biopharmaceutical production have necessitated a
deeper understanding of the factors influencing cell culture viability, particularly within …